Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Summary
is acting as lead manager for the offering.A shelf registration statement relating to these securities has been filed with the (SEC) and became effective on . The companys lead candidate, pegozafermin, is in clinical development for the treatment of non-alcoholic steatohepatitis ( ) and severe hypertriglyceridemia (SHTG). Words such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, anticipate, goal, opportunity, develop, plan or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.